Award Year / Program / Phase:2009 / SBIR / Phase I
Agency:HHS
Principal Investigator:Vicki Nienaber
Award Amount:$328,829.00
Abstract:
DESCRIPTION (provided by applicant): Our aim is to discover novel safety assessment candidates (pre-clinical compounds) for the treatment of cancer by targeting the receptor tyrosine kinase (RTK), anaplastic lymphoma kinase (ALK). It is now proven that ALK
has a widespread pathogenic involvement in… More
Award Year / Program / Phase:2010 / SBIR / Phase I
Agency:HHS
Principal Investigator:Vicki Nienaber
Award Amount:$456,299.00
Abstract:
DESCRIPTION (provided by applicant): Bacterial resistance to antibiotics has been an evolving problem since the dawn of the antibiotics era, requiring consistent scientific advances over the years in antibiotic discovery, epidemiological surveillance and i
nfection control techniques to overcome the… More